We investigated the effect of TRI-03 on TrxR1 activity in melanoma cells and found that TRI-03 administration significantly inhibited TrxR1 activity in a dose-dependent manner, whereas auranofin had only a moderate effect (Figure 3A). This evidence concerns the gene TXNRD1 and melanoma.